Home CDH1 (E-cadherin) expression independently affects clinical outcome in acute myeloid leukemia with normal cytogenetics
Article
Licensed
Unlicensed Requires Authentication

CDH1 (E-cadherin) expression independently affects clinical outcome in acute myeloid leukemia with normal cytogenetics

  • Ting-juan Zhang , Jing-dong Zhou , Ji-chun Ma , Zhao-qun Deng , Zhen Qian , Dong-ming Yao , Jing Yang , Xi-xi Li , Jiang Lin EMAIL logo and Jun Qian EMAIL logo
Published/Copyright: June 15, 2016
Become an author with De Gruyter Brill
Submit Manuscript Author Information
Clinical Chemistry and Laboratory Medicine (CCLM)
From the journal Clinical Chemistry and Laboratory Medicine (CCLM) Volume 55 Issue 1

Abstract

Background:

Epithelial-mesenchymal transition (EMT) is a critical process which involves in tumor metastasis. As an important EMT marker gene, CDH1 (E-cadherin) expression and its clinical implication in acute myeloid leukemia (AML) remain largely elusive.

Methods:

Real-time quantitative PCR (RQ-PCR) was carried out to examine CDH1 transcript level in 123 de novo AML patients and 34 controls.

Results:

Compared with controls, CDH1 was significantly downregulated in AML (p<0.001). The median level of CDH1 expression divided total AML patients into CDH1 low-expressed (CDH11ow) and CDH1 high-expressed (CDH1high) groups. There were no significant differences between the two groups in age, peripheral blood cell counts, complete remission (CR) rate, and the distribution of FAB/WHO subtypes as well as karyotypes/karyotypic classifications (p>0.05). However, CDH11ow group tended to have a higher bone marrow (BM) blasts (p=0.093). The spearman correlation analysis further illustrated a trend towards a negative correlation between CDH1 expression level and BM blasts (r=–0.214, p=0.052). CDH1low group had a tendency towards a lower frequency of N/K-RAS mutations (p=0.094). Furthermore, CDH1low patients had markedly shorter overall survival (OS) time in cytogenetic normal AML (CN-AML) (p=0.019). Both univariate and multivariate analyses confirmed the prognostic value of CDH1 expression in CN-AML patients (p=0.027 and 0.033, respectively).

Conclusions:

CDH1 downregulation acted as an independent prognostic biomarker in CN-AML patients.

Keywords: acute myeloid leukemia; CDH1 (E-cadherin); expression; prognosis
Corresponding authors: Jun Qian, MD, Department of Hematology, Affiliated People’s Hospital of Jiangsu University, 8 Dianli Rd., 212002 Zhenjiang, Jiangsu, P.R. China, Fax: +86 511 85234387; and Jiang Lin, PhD, Laboratory Center, Affiliated People’s Hospital of Jiangsu University, 8 Dianli Rd., 212002 Zhenjiang, Jiangsu, P.R. China, Fax: +86 511 85234387
aTing-juan Zhang and Jing-dong Zhou contributed equally to this work.

Funding source: National Natural Science Foundation of China

Award Identifier / Grant number: 81270630

Award Identifier / Grant number: 81172592

Funding source: Jiangsu University

Award Identifier / Grant number: JLY20140018

Funding statement: This study was supported by the National Natural Science foundation of China (81270630, 81172592), Science and Technology Special Project in Clinical Medicine of Jiangsu Province (BL2012056), 333 Project of Jiangsu Province (BRA2013136), Six talent peaks project in Jiangsu Province (2015-WSN-115), Science and Technology Infrastructure Program of Zhenjiang (SS2012003), Social Development Foundation of Zhenjiang (SH2014086, SH2014044, SH2015058), Clinical Medical Science, Development Foundation of Jiangsu University (JLY20140018), Key Medical Talent Program of Zhenjiang City.

  1. Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

  2. Research funding: This study was supported by the National Natural Science foundation of China (81270630, 81172592), Science and Technology Special Project in Clinical Medicine of Jiangsu Province (BL2012056), 333 Project of Jiangsu Province (BRA2013136), Six talent peaks project in Jiangsu Province (2015-WSN-115), Science and Technology Infrastructure Program of Zhenjiang (SS2012003), Social Development Foundation of Zhenjiang (SH2014086, SH2014044, SH2015058), Clinical Medical Science, Development Foundation of Jiangsu University (JLY20140018), Key Medical Talent Program of Zhenjiang City.

  3. Employment or leadership: None declared.

  4. Honorarium: None declared.

  5. Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.

References

1. Eisfeld AK, Marcucci G, Maharry K, Schwind S, Radmacher MD, Nicolet D, et al. MiR-3151 interplays with its host gene BAALC and independently affects outcome of patients with cytogenetically normal acute myeloid leukemia. Blood 2012;120:249–58.10.1182/blood-2012-02-408492Search in Google Scholar

2. Wiseman DH, Greystoke BF, Somervaille TC. The variety of leukemic stem cells in myeloid malignancy. Oncogene 2014;33:3091–8.10.1038/onc.2013.269Search in Google Scholar

3. Yan W, Xu L, Sun Z, Lin Y, Zhang W, Chen J, et al. MicroRNA biomarker identification for pediatric acute myeloid leukemia based on a novel bioinformatics model. Oncotarget 2015;6:26424–36.10.18632/oncotarget.4459Search in Google Scholar

4. Estey E, Döhner H. Acute myeloid leukaemia. Lancet 2006;368:1894–1907.10.1016/S0140-6736(06)69780-8Search in Google Scholar

5. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children’s Leukaemia Working Parties. Blood 1998;92:2322–33.10.1182/blood.V92.7.2322Search in Google Scholar

6. Chuang MK, Chiu YC, Chou WC, Hou HA, Tseng MH, Kuo YY, et al. An mRNA expression signature for prognostication in de novo acute myeloid leukemia patients with normal karyotype. Oncotarget 2015;6:39098–110.10.18632/oncotarget.5390Search in Google Scholar PubMed PubMed Central

7. Bou Samra E, Klein B, Commes T, Moreaux J. Development of gene expression-based risk score in cytogenetically normal acute myeloid leukemia patients. Oncotarget 2012;3:824–32.10.18632/oncotarget.571Search in Google Scholar PubMed PubMed Central

8. Bernaudo S, Salem M, Qi X, Zhou W, Zhang C, Yang W, et al. Cyclin G2 inhibits epithelial-to-mesenchymal transition by disrupting Wnt/β-catenin signaling. Oncogene 2016.10.1038/onc.2016.15Search in Google Scholar PubMed PubMed Central

9. Yang J, Zhang X, Zhang Y, Zhu D, Zhang L, Li Y, et al. HIF-2α promotes epithelial-mesenchymal transition through regulating Twist2 binding to the promoter of E-cadherin in pancreatic cancer. J Exp Clin Cancer Res 2016;35:26.10.1186/s13046-016-0298-ySearch in Google Scholar PubMed PubMed Central

10. Gumbiner BM. Regulation of cadherin adhesive activity. J Cell Biol 2000;148:399–404.10.1083/jcb.148.3.399Search in Google Scholar PubMed PubMed Central

11. Greco M, D’Alò F, Scardocci A, Criscuolo M, Fabiani E, Guidi F, et al. Promoter methylation of DAPK1, E-cadherin and thrombospondin-1 in de novo and therapy-related myeloid neoplasms. Blood Cells Mol Dis 2010;45:181–5.10.1016/j.bcmd.2010.05.008Search in Google Scholar PubMed

12. Li S, Qin X, Chai S, Qu C, Wang X, Zhang H. Modulation of E-cadherin expression promotes migration ability of esophageal cancer cells. Sci Rep 2016;6:21713.10.1038/srep21713Search in Google Scholar PubMed PubMed Central

13. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. Proposed revised criteria for the classification of acute myeloid leukaemia. A report of the French-American-British Cooperative Group. Ann Intern Med 1985;103:620–5.10.7326/0003-4819-103-4-620Search in Google Scholar PubMed

14. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon, France: IARC Press, 2008.Search in Google Scholar

15. Li Y, Lin J, Yang J, Qian J, Qian W, Yao DM, et al. Overexpressed let-7a-3 is associated with poor outcome in acute myeloid leukemia. Leuk Res 2013;37:1642–7.10.1016/j.leukres.2013.09.022Search in Google Scholar PubMed

16. Zhou JD, Yao DM, Zhang YY, Ma JC, Wen XM, Yang J, et al. GPX3 hypermethylation serves as an independent prognostic biomarker in non-M3 acute myeloid leukemia. Am J Cancer Res 2015;5:2047–55.Search in Google Scholar

17. Zhou JD, Yang L, Zhang YY, Yang J, Wen XM, Guo H, et al. Overexpression of BAALC: clinical significance in Chinese de novo acute myeloid leukemia. Med Oncol 2015;32:386.10.1007/s12032-014-0386-9Search in Google Scholar PubMed

18. Tang CY, Lin J, Qian W, Yang J, Ma JC, Deng ZQ, et al. Low SOX17 expression: prognostic significance in de novo acute myeloid leukemia with normal cytogenetics. Clin Chem Lab Med 2014;52:1843–50.10.1515/cclm-2014-0487Search in Google Scholar PubMed

19. Wen XM, Lin J, Yang J, Yao DM, Deng ZQ, Tang CY, et al. Double CEBPA mutations are prognostically favorable in non-M3 acute myeloid leukemia patients with wild-type NPM1 and FLT3-ITD. Int J Clin Exp Pathol 2014;7:6832–40.Search in Google Scholar

20. Wen XM, Hu JB, Yang J, Qian W, Yao DM, Deng ZQ, et al. CEBPA methylation and mutation in myelodysplastic syndrome. Med Oncol 2015;32:192.10.1007/s12032-015-0605-zSearch in Google Scholar PubMed

21. Yang X, Qian J, Sun A, Lin J, Xiao G, Yin J, et al. RAS mutation analysis in alarge cohort of Chinese patients with acute myeloid leukemia. Clin Biochem 2013;46:579–83.10.1016/j.clinbiochem.2012.12.022Search in Google Scholar PubMed

22. Lin J, Yao DM, Qian J, Chen Q, Qian W, Li Y, et al. Recurrent DNMT3A R882 mutations in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome. PLoS One 2011;6:e26906.10.1371/journal.pone.0026906Search in Google Scholar PubMed PubMed Central

23. Lin J, Yao DM, Qian J, Chen Q, Qian W, Li Y, et al. IDH1 and IDH2 mutation analysis in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome. Ann Hematol 2012;91:519–25.10.1007/s00277-011-1352-7Search in Google Scholar PubMed

24. Qian J, Yao DM, Lin J, Qian W, Wang CZ, Chai HY, et al. U2AF1 Mutations in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome. PLoS One 2012;7:e45760.10.1371/journal.pone.0045760Search in Google Scholar PubMed PubMed Central

25. Larue L, Bellacosa A. Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 3′ kinase/AKT pathways. Oncogene 2005;24:7443–54.10.1038/sj.onc.1209091Search in Google Scholar PubMed

26. Wang F, Ma L, Zhang Z, Liu X, Gao H, Zhuang Y, et al. Hedgehog signaling regulates epithelial-mesenchymal transition in pancreatic cancer stem-like cells. J Cancer 2016;7:408–17.10.7150/jca.13305Search in Google Scholar PubMed PubMed Central

27. Sougleri IS, Papadakos KS, Zadik MP, Mavri-Vavagianni M, Mentis AF, Sgouras DN. Helicobacter pylori CagA protein induces factors involved in the epithelial to mesenchymal transition (EMT) in infected gastric epithelial cells in an EPIYA-phosphorylation-dependent manner. FEBS J 2016;283:206–20.10.1111/febs.13592Search in Google Scholar PubMed

28. Serrano-Gomez SJ, Maziveyi M, Alahari SK. Regulation of epithelial-mesenchymal transition through epigenetic and post-translational modifications. Mol Cancer 2016;15:18.10.1186/s12943-016-0502-xSearch in Google Scholar PubMed PubMed Central

29. Zeng W, Zhu J, Shan L, Han Z, Aerxiding P, Quhai A, et al. The clinicopathological significance of CDH1 in gastric cancer: a meta-analysis and systematic review. Drug Des Devel Ther 2015;9:2149–57.10.2147/DDDT.S75429Search in Google Scholar PubMed PubMed Central

30. Kim SA, Inamura K, Yamauchi M, Nishihara R, Mima K, Sukawa Y, et al. Loss of CDH1 (E-cadherin) expression is associated with infiltrative tumour growth and lymph node metastasis. Br J Cancer 2016;114:199–206.10.1038/bjc.2015.347Search in Google Scholar PubMed PubMed Central

31. Chen X, Wang Y, Xia H, Wang Q, Jiang X, Lin Z, et al. Loss of E-cadherin promotes the growth, invasion and drug resistance of colorectal cancer cells and is associated with liver metastasis. Mol Biol Rep 2012;39:6707–14.10.1007/s11033-012-1494-2Search in Google Scholar PubMed

32. Lu MH, Huang CC, Pan MR, Chen HH, Hung WC. Prospero homeobox 1 promotes epithelial-mesenchymal transition in colon cancer cells by inhibiting E-cadherin via miR-9. Clin Cancer Res 2012;18:6416–25.10.1158/1078-0432.CCR-12-0832Search in Google Scholar PubMed

33. Grille SJ, Bellacosa A, Upson J, Klein-Szanto AJ, van Roy F, Lee-Kwon W, et al. The protein kinase Akt induces epithelial mesenchymal transition and promotes enhanced motility and invasiveness of squamous cell carcinoma lines. Cancer Res 2003;63:2172–8.Search in Google Scholar

34. Pei Y, Wang P, Liu H, He F, Ming L. FOXQ1 promotes esophageal cancer proliferation and metastasis by negatively modulating CDH1. Biomed Pharmacother 2015;74:89–94.10.1016/j.biopha.2015.07.010Search in Google Scholar PubMed

35. Sowa T, Menju T, Sonobe M, Nakanishi T, Shikuma K, Imamura N, et al. Association between epithelial-mesenchymal transition and cancer stemness and their effect on the prognosis of lung adenocarcinoma. Cancer Med 2015;4:1853–62.10.1002/cam4.556Search in Google Scholar PubMed PubMed Central

36. Yue B, Qiu S, Zhao S, Liu C, Zhang D, Yu F, et al. LncRNA-ATB mediated E-cadherin repression promotes the progression of colon cancer and predicts poor prognosis. J Gastroenterol Hepatol 2016;31:595–603.10.1111/jgh.13206Search in Google Scholar PubMed

37. Peng J, Qi S, Wang P, Li W, Song L, Liu C, et al. Meta-analysis of downregulated E-cadherin as a poor prognostic biomarker for cervical cancer. Future Oncol 2016;12:715–26.10.2217/fon.15.332Search in Google Scholar PubMed

38. Melki JR, Vincent PC, Brown RD, Clark SJ. Hypermethylation of E-cadherin in leukemia. Blood 2000;95:3208–13.10.1182/blood.V95.10.3208Search in Google Scholar

39. Bullinger L, Döhner K, Bair E, Fröhling S, Schlenk RF, Tibshirani R, et al. Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. N Engl J Med 2004;350:1605–16.10.1056/NEJMoa031046Search in Google Scholar PubMed

40. Metzeler KH, Hummel M, Bloomfield CD, Spiekermann K, Braess J, Sauerland MC, et al. An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia. Blood 2008;112:4193–201.10.1182/blood-2008-02-134411Search in Google Scholar PubMed PubMed Central

41. Corn PG, Smith BD, Ruckdeschel ES, Douglas D, Baylin SB, Herman JG. E-cadherin expression is silenced by 5′ CpG island methylation in acute leukemia. Clin Cancer Res 2000;6:4243–8.Search in Google Scholar

42. Aggerholm A, Holm MS, Guldberg P, Olesen LH, Hokland P. Promoter hypermethylation of p15INK4B, HIC1, CDH1, and ER is frequent in myelodysplastic syndrome and predicts poor prognosis in early-stage patients. Eur J Haematol 2006;76:23–32.10.1111/j.1600-0609.2005.00559.xSearch in Google Scholar PubMed

43. Shimamoto T, Ohyashiki JH, Ohyashiki K. Methylation of p15(INK4b) and E-cadherin genes is independently correlated with poor prognosis in acute myeloid leukemia. Leuk Res 2005;29:653–9.10.1016/j.leukres.2004.11.014Search in Google Scholar PubMed

44. Renneville A, Roumier C, Biggio V, Nibourel O, Boissel N, Fenaux P, et al. Cooperating gene mutations in acute myeloid leukemia: a review of the literature. Leukemia 2008;22:915–31.10.1038/leu.2008.19Search in Google Scholar PubMed

45. Schmidt CR, Washington MK, Gi YJ, Coffey RJ, Beauchamp RD, Pearson AS. Dysregulation of E-cadherin by oncogenic Ras in intestinal epithelial cells is blocked by inhibiting MAP kinase. Am J Surg 2003;186:426–30.10.1016/j.amjsurg.2003.07.004Search in Google Scholar PubMed

46. Khan P, Manna A, Saha S, Mohanty S, Mukherjee S, Mazumdar M, et al. Aspirin inhibits epithelial-to-mesenchymal transition and migration of oncogenic K-ras-expressing non-small cell lung carcinoma cells by down-regulating E-cadherin repressor Slug. BMC Cancer 2016;16:39.10.1186/s12885-016-2078-7Search in Google Scholar PubMed PubMed Central

Received: 2016-3-12
Accepted: 2016-5-7
Published Online: 2016-6-15
Published in Print: 2017-1-1

©2017 Walter de Gruyter GmbH, Berlin/Boston

Articles in the same Issue

  1. Frontmatter
  2. Editorial
  3. Describing children’s changes using clinical chemistry analytes
  4. Review
  5. Assessment of vitamin D status – a changing landscape
  6. Opinion Papers
  7. Order of blood draw: Opinion Paper by the European Federation for Clinical Chemistry and Laboratory Medicine (EFLM) Working Group for the Preanalytical Phase (WG-PRE)
  8. The principles of Health Technology Assessment in laboratory medicine
  9. Genetics and Molecular Diagnostics
  10. Functional polymorphism of lncRNA MALAT1 contributes to pulmonary arterial hypertension susceptibility in Chinese people
  11. General Clinical Chemistry and Laboratory Medicine
  12. Influence of pneumatic tube system transport on routinely assessed and spectrophotometric cerebrospinal fluid parameters
  13. Estimation of hematocrit in filter paper dried bloodspots by potassium measurement: advantage of use of perimeter ring samples over circular center sub-punch samples
  14. Evaluation of the first fully automated immunoassay method for the measurement of stimulating TSH receptor autoantibodies in Graves’ disease
  15. Comparison of four immunoassays to measure serum ferritin concentrations and iron deficiency prevalence among non-pregnant Cambodian women and Congolese children
  16. Activity and expression of dipeptidyl peptidase IV on peripheral blood mononuclear cells in patients with early steroid and disease modifying antirheumatic drugs naïve rheumatoid arthritis
  17. Hematology and Coagulation
  18. Neutrophil CD64 Index as a superior biomarker for early diagnosis of infection in febrile patients in the hematology department
  19. Dilute Russell’s viper venom time reagents in lupus anticoagulant testing: a well-considered choice
  20. Reference Values and Biological Variations
  21. Pediatric reference intervals for alkaline phosphatase
  22. Cancer Diagnostics
  23. Transcript expression and genetic variability analysis of caspases in breast carcinomas suggests CASP9 as the most interesting target
  24. CDH1 (E-cadherin) expression independently affects clinical outcome in acute myeloid leukemia with normal cytogenetics
  25. Cardiovascular Diseases
  26. Association of monocyte to HDL cholesterol level with contrast induced nephropathy in STEMI patients treated with primary PCI
  27. Low concentrations of adropin are associated with endothelial dysfunction as assessed by flow-mediated dilatation in patients with metabolic syndrome
  28. Preoperative serum potassium predicts the clinical outcome after non-cardiac surgery
  29. Diabetes
  30. A simple colorimetric assay for measuring fructosamine 3 kinase activity
  31. Acknowledgment
  32. Acknowledgment
  33. Letters to the Editor
  34. Normalisation issues in glucose measurements using phlebotomy tubes with liquid additives
  35. Utility of dilution tests in investigating interference in the free thyroxine assay
  36. Plasminogen activator inhibitor-1 as a marker of cardiovascular response in professional mountain ultra-marathon runners
  37. Pitfalls of LSD screening assays: comparison of KIMS and CEDIA immunoassays with LC-MS
  38. A two site comparison of two point-of-care activated clotting time systems
  39. Detection of the common South-East Asian β0-thalassemia mutations in samples with borderline HbA2 levels
  40. Biclonal plasma cell myeloma with the simultaneous appearance of both secretory lambda and nonsecretory kappa monoclonal light chains
https://doi.org/10.1515/cclm-2016-0205
Keywords for this article
acute myeloid leukemia; CDH1 (E-cadherin); expression; prognosis

Articles in the same Issue

  1. Frontmatter
  2. Editorial
  3. Describing children’s changes using clinical chemistry analytes
  4. Review
  5. Assessment of vitamin D status – a changing landscape
  6. Opinion Papers
  7. Order of blood draw: Opinion Paper by the European Federation for Clinical Chemistry and Laboratory Medicine (EFLM) Working Group for the Preanalytical Phase (WG-PRE)
  8. The principles of Health Technology Assessment in laboratory medicine
  9. Genetics and Molecular Diagnostics
  10. Functional polymorphism of lncRNA MALAT1 contributes to pulmonary arterial hypertension susceptibility in Chinese people
  11. General Clinical Chemistry and Laboratory Medicine
  12. Influence of pneumatic tube system transport on routinely assessed and spectrophotometric cerebrospinal fluid parameters
  13. Estimation of hematocrit in filter paper dried bloodspots by potassium measurement: advantage of use of perimeter ring samples over circular center sub-punch samples
  14. Evaluation of the first fully automated immunoassay method for the measurement of stimulating TSH receptor autoantibodies in Graves’ disease
  15. Comparison of four immunoassays to measure serum ferritin concentrations and iron deficiency prevalence among non-pregnant Cambodian women and Congolese children
  16. Activity and expression of dipeptidyl peptidase IV on peripheral blood mononuclear cells in patients with early steroid and disease modifying antirheumatic drugs naïve rheumatoid arthritis
  17. Hematology and Coagulation
  18. Neutrophil CD64 Index as a superior biomarker for early diagnosis of infection in febrile patients in the hematology department
  19. Dilute Russell’s viper venom time reagents in lupus anticoagulant testing: a well-considered choice
  20. Reference Values and Biological Variations
  21. Pediatric reference intervals for alkaline phosphatase
  22. Cancer Diagnostics
  23. Transcript expression and genetic variability analysis of caspases in breast carcinomas suggests CASP9 as the most interesting target
  24. CDH1 (E-cadherin) expression independently affects clinical outcome in acute myeloid leukemia with normal cytogenetics
  25. Cardiovascular Diseases
  26. Association of monocyte to HDL cholesterol level with contrast induced nephropathy in STEMI patients treated with primary PCI
  27. Low concentrations of adropin are associated with endothelial dysfunction as assessed by flow-mediated dilatation in patients with metabolic syndrome
  28. Preoperative serum potassium predicts the clinical outcome after non-cardiac surgery
  29. Diabetes
  30. A simple colorimetric assay for measuring fructosamine 3 kinase activity
  31. Acknowledgment
  32. Acknowledgment
  33. Letters to the Editor
  34. Normalisation issues in glucose measurements using phlebotomy tubes with liquid additives
  35. Utility of dilution tests in investigating interference in the free thyroxine assay
  36. Plasminogen activator inhibitor-1 as a marker of cardiovascular response in professional mountain ultra-marathon runners
  37. Pitfalls of LSD screening assays: comparison of KIMS and CEDIA immunoassays with LC-MS
  38. A two site comparison of two point-of-care activated clotting time systems
  39. Detection of the common South-East Asian β0-thalassemia mutations in samples with borderline HbA2 levels
  40. Biclonal plasma cell myeloma with the simultaneous appearance of both secretory lambda and nonsecretory kappa monoclonal light chains
Sign up now to receive a 20% welcome discount
Institutional Access
How does access work?
Have an idea on how to improve our website?
Please write us.
© 2025 De Gruyter Brill
Downloaded on 28.9.2025 from https://www.degruyterbrill.com/document/doi/10.1515/cclm-2016-0205/html
Scroll to top button